

The CRISPR-Cas System

Subjects: Biotechnology & Applied Microbiology

Contributor: Daniel S. Dezmirean, Adela Ramona Moise, Gabriela-Maria Baci, ALEXANDRA-ANTONIA CUCU, Otilia Bobis, Attila Ratiu

CRISPR (clustered regularly interspaced short palindromic repeats)-Cas (CRISPR-associated) represents a powerful genome editing technology that revolutionized in a short period of time numerous natural sciences branches. Therefore, extraordinary progress was made in various fields, such as entomology or biotechnology.

Keywords: CRISPR-Cas ; genome engineering ; insect biotechnology ; applied biotechnology

1. Introduction

The life sciences research fields were revolutionized by the outstanding development of various genome editing tools. By using specific techniques of genome editing, the genomic DNA of every living organism can be submitted to guided changes, such as deletions, insertions, and sequence substitutions ^[1].

In recent years, several genome editing tools have been in the spotlight. Among them, there are three remarkable technologies, namely those relying on programmable nucleases (i.e., the transcription activator like effector nucleases (TALENs)), zinc finger nucleases (ZFNs), and clustered regularly interspaced short palindromic repeat - associated nucleases (CRISPR-Cas) ^{[2][3]}. Currently, by using engineered nucleases, remarkable advances are being made regarding the correction of genetic mutations, gene expression regulation, and the development of therapeutic agents; these approaches are also used for a better understanding of gene functions and the mechanisms underlying the development of certain genetic disorders or various diseases ^[4].

When it comes to genome editing, it is crucial to avoid off-target effects, but overall, the CRISPR-Cas system exhibits reliable results, owing to a great degree of fidelity ^{[4][5]}. Since its discovery in bacteria, the CRISPR-Cas system has been continuously exploited, representing an extremely versatile tool for the scientific community due to its reprogrammable feature. Currently, this system is used to edit the genomes of various organisms, such as bacteria, insects, plants, or human cells ^[6].

2. The CRISPR-Cas System

CRISPR-Cas is one of the key methods employed by many molecular biology scientific laboratories. Since its first description ^[7], genome editing focused research was implemented by countless research groups ^{[8][9][10]}.

2.1. The CRISPR-Cas Complex Role in the Immunity System

When investigating the iap gene product in the opportunistic pathogen *Escherichia coli*, Ishino et al. (1987) ^[11] observed an atypical structure, specifically the repetition of several homologous sequences. Later, this type of structure was observed in various bacterial, as well as archaeal strains ^{[12][13]}. Subsequently, these repetitive sequences were linked with exogenous genetic material, and following several years, their assembling mechanism and function were elucidated ^[14]. This type of sequence can be placed on the chromosomal DNA, but it can also be found on the plasmid DNA ^[15].

The scientists demonstrated that CRISPR-Cas, which is present in one-third of bacteria and nearly in all archaea, has a key role in host's adaptive immunity. It protects the organism against various intruders, such as viruses, but it also offers protection against other mobile genetic elements, such as transposons or plasmids ^[16].

The CRISPR-Cas system structure includes three main components, i.e., the CRISPR arrays, the associated Cas proteins, and the leader nucleotide sequence. The first genetic component, the CRISPR locus, is characterized by identical repeats structures (21–37 bp) that are highly conserved and the spacer sequences that are acquired fragments of invader's nucleic acid material. The CRISPR array is located downstream from cas genes. The latter encodes for Cas proteins that are crucial to the immune reaction ^[17].

Initially, only four distinct Cas proteins (1–4) were reported, due to the rapid evolution of biological sciences; currently, there numerous Cas proteins have been described ^{[18][19]}, Cas1 being the most analyzed ^[20].

CRISPR-Cas has a great adaptability, with host-related specificities; thus, it exhibits a significant diversity. The varying feature is defined by the CRISPR array and the cas gene sequences. The classification of these types of systems is based on the signature Cas proteins. Currently, there are two major classes of CRISPR-Cas systems, each also di-vided in several groups ^[21]. Regarding the leader nucleotide sequence, it has been shown that it has a key role by carrying the essential promoter sequences for the transcription of CRISPR loci. Besides the promoter, the leader contains specific signals that are crucial for the adaptation stage from the first phase of CRISPR-Cas activation ^[22].

The adaptation is the first functional stage of the CRISPR-Cas mechanism, during which the foreign nucleic acid is recognized by several Cas proteins ^[23] and consequently integrated next to a leader sequence. Through this mechanism, in evolution, the spacers are arranged chronologically, and this feature helps bacteria and archaea to enhance their protection against the genetic material of the latest foreign encounter ^[24]. Each new acquired spacer is accompanied by a repeat sequence; therefore, the CRISPR array expands with every invasion ^[25].

The CRISPR array is transcribed in the second step, specifically in the biogenesis phase ^[26]. First of all, it is being transcribed into a precursor CRISPR RNA (crRNA). At the end of this phase, there are numerous mature crRNAs molecules, resulting from the action of RNase III that process the precursor crRNA. Each crRNA includes a spacer and a repeat sequence ^{[24][27][28]}.

The last step of the system's mechanism is the interference phase. It involves the degradation of the foreign nucleic acid, by targeting and cleaving it ^[29]. The products of the biogenesis phase, the crRNAs, act like guides for targeting the invader, which is then cleaved following a Cas proteins cascade that act like molecular scissors ^[30].

2.2. The CRISPR-Cas System as a Genome Editing Tool

When it comes to leading tools in genetic engineering, the CRISPR-Cas system can be considered the foremost instrument. After elucidating its function in various organisms, scientists aimed to exploit its versatility, in order to overcome the disadvantages of other available genome editing tools ^[31]. Even if scientific studies still report the use of ZFNs and TALENs techniques as editing tools, the CRISPR-Cas system is the most effective genome editing instrument, standing on top in regards to efficiency, cost-effectiveness, and the relative simplicity of use ^[32] (**Table 1**). Another considerable advantage of this system is represented by its capacity to simultaneously target multiple genes ^[33].

Table 1. Comparison between TALEN, ZFN, and CRISPR-Cas gene editing technologies.

Traits	TALEN	ZFN	CRISPR-Cas	References
Origin	Prokaryotic	Eukaryotic	Prokaryotic	^[34]
Efficiency (%)	76	12	81	^[35]
Specificity	Moderate	Low	High	^{[36][37][38][39]}
Target site recognition	Any site	Any site	Pam motif (NGG) required	^[36]
Multiplex potential	Low	Low	High	^{[36][38]}
Processing time	Time consuming	Time consuming	Short	^[38]
Methylation sensitive	Sensitive	Sensitive	Not sensitive	^[35]
Engineering feasibility	Moderate/High	Moderate	Moderate/High	^{[35][38]}

Traits	TALEN	ZFN	CRISPR-Cas	References
Dimerization required	Yes	Yes	No	[37]
Cost effectiveness	Moderate	No	Yes	[36][37]

Of the numerous CRISPR-Cas systems, CRISPR-Cas9 is currently the most used instrument in laboratories across the world [40]. The Cas9 nuclease is the signature protein of CRISPR-Cas II systems and it is responsible for double strand DNA breaks [20]. Three different methods to deliver the Cas9 endonuclease have been described. It can be directly delivered by microinjection into the embryos, while the other two delivery methods involve a plasmid that expresses the Cas9 enzyme, or a messenger RNA (mRNA) sequence that encodes it. Of the three techniques, in terms of genome engineering, the earliest mentioned is the best option due to its certain advantages. By directly delivering the protein, low immunogen effects were observed. Furthermore, the off-target activity is minimized compared with the other two methods [41]. The use of CRISPR-Cas9 is a simple but powerful genome editing tool, with various implementations, and their impact on new research trends has been reviewed elsewhere [42].

The CRISPR-Cas9 mechanism relies on the Cas9 nuclease and a guide sequence (gRNA). As the name implies, the gRNA has the role to guide the Cas9 nuclease to a target site in order to cleave the DNA. The key feature of gRNA is the extensive complementarity with the target sequence [43]. The protospacer-adjacent motif (PAM) bordering the target complementary sequence has a key role, since in its absence, the CRISPR-Cas systems would degrade their own CRISPR loci. In order to perform a cleavage, the Cas9 protein scans for the PAM sequence. Even if the gRNA is complementary with the target sequence, the Cas9 endonuclease will not cleave it in the absence of PAM [44].

The central factor that influences the success of the gene editing process is the repair path of the double-strand breaks produced by Cas9. There are two main repair pathways: the homology-directed repair (HDR) and the nonhomologous end joining (NHEJ), respectively [45]. More often, NHEJ is exploited in order to acquire indels mutations, specially to obtain small deletions. These deletions are extremely useful for disclosing gene functions [46]. However, the HDR machinery is used not just to obtain knock-out or knock-down mutations, such as the expected output following NHEJ, but to generate target knock-ins. Therefore, by using HDR, exogenous sequences can be successfully integrated into the host's genome. Currently, major efforts are being made in order to enhance the sequence replacement by using the HDR mechanism [47].

CRISPR-Cas9 is currently used in multiple research fields, such as agriculture (editing of various agricultural plant genomes or pest insect's genome) [48][49][50], biotechnology, food industry, and medicine (modeling diseases using HeLa cells, deciphering HIV infection mechanisms, using various experimental models, such as *Danio rerio* to tackle cancer and neurological diseases, etc.) [51][52], just to mention a few (**Figure 1**) [53].




Figure 1. Schematic representation of the most important current applications of CRISPR-Cas9 in entomology, medicine, and agriculture. On top, a simplified description of CRISPR-Cas9 applicability in *B. mori* that is extensively described in the main text (created with BioRender.com, accessed on 2 December 2021).

2.3. CRISPR-Cas9 in Entomology

Being the most diverse and numerous category of organisms for decades [54], insects have been intensively studied. Countless studies have been performed due to insects' key roles in ecology, agriculture, and medicine [55][56]. Considering this, numerous research groups aimed to use the CRISPR-Cas9 system to manipulate the insects' genome. The first application of CRISPR-Cas9 was performed in *Drosophila melanogaster* [57] due to its strategic importance as arguably the main experimental model organism for life sciences [58]. Besides *D. melanogaster*, the researchers also used the CRISPR-Cas9 applicability on *B. mori*, *Apis mellifera*, *Aedes aegypti*, and *Tribolium castaneum* [59][60].

Gratz et al. (2013) [61] programmed CRISPR-Cas9 to edit *Drosophila's* genome. The authors targeted the yellow gene, which is commonly used in various studies. First, they aimed to determine if this genome engineering tool could be efficient and could fulfill its role to induce breaks in the target sequence. By using the CRISPR-Cas9 system in *Drosophila*, not only was the yellow gene successfully knocked out, but the genome's alterations were also germline transmitted. Subsequent to the deletion of the target gene, a donor sequence was designed. This sequence provided the template for the HDR repair pathway and its use was to test the accuracy of specific replacement of yellow gene with an exogenous sequence. These sequence replacements were transmitted to descendants as well. Their data showed that there was no off-target activity and it highlighted the feasibility of using the CRISPR-Cas9 technology in eukaryotes [61].

Aiming to further highlight the feasibility of choosing this system to perform genome alteration in *Drosophila*, Yu et al. (2013) [62] designed two gRNAs to induce mutations in two regions of the yellow gene. In addition, they targeted other six sequences, both euchromatic and heterochromatic loci. Remarkably, a definite mutation in *ms(3)k81* was transmitted to descendants in a proportion of 100%. By successfully targeting heterochromatic loci, their result showed that the CRISPR-Cas9 system is efficient for altering the heterochromatin [62]. *Drosophila* have been used in numerous studies in order to examine the insecticide resistance [63][64][65]. In this direction, Douris et al. (2020) [49] notably summarized the progress in using CRISPR-Cas9 to explore the genetic basis of this mechanism.

The CRISPR-Cas9 technique was used to perform functional analysis concomitantly on two genes belonging to the cricket (*Gryllus bimaculatus*) [66]. *G. bimaculatus* is an important insect for experimental studies; for example, it plays an important role for evolutionary developmental studies and comparative biology, but it is also a relevant model organism for neurobiology and behavioral sciences [67]. The efficiency of inserting a donor sequence via a homology-independent technique was tested in two *hox* genes, namely *Gb-Ubx* and *Gb-abd-A*. After inserting the donor fragment into essential exons of both genes, their function was lost. Thus, functional investigations of *hox* genes could be carried out by using the knock-in/knock-out approaches [66].

Being one of the most important social insects [68] and as it plays a crucial role as a pollinator, the honeybee (*Apis mellifera*) has been intensively studied. It also plays a pivotal role in various therapeutic areas due to honey production. This natural product has extraordinary benefits for human health, exhibiting antioxidant, antiviral, and antibacterial effects [69]. Due to its special characteristics, the use of honey is not limited to humans, but this natural product is being used to improve certain features of other insects, such as silkworms [70]. There are numerous studies that detail functional analysis of *A. mellifera* genes by exploiting the CRISPR-Cas9 system. For instance, Hu et al. (2019) [60] reported the successful utilization of this system for knocking out the *mrjp 1* gene from the honeybee genome. The CRISPR-Cas9 complex was delivered through microinjection and they tested two specific regions of embryos, for identifying the most convenient structure for delivering the gRNA and the Cas9 endonuclease. By microinjecting the construct at the dorsal posterior side, there was a low rate of successful manipulation (11.8%); however, when choosing the ventral cephalic side, the results showed a great rate of gene editing (93.3%). Trying to validate the previous results, the authors also targeted *pax6*. Based on the previously obtained results, they microinjected the CRISPR-Cas9 construct at the ventral cephalic side. The results showed an editing rate of 100% [60]. Targeting the same gene, *mrjp 1*, similar results have been obtained in another study [71]. Thus, functional analysis of *A. mellifera* genes can be effectively performed by using the CRISPR-Cas9 system.

Considering the same topic of gene function research, Nie et al. (2021) [72] used the CRISPR-Cas9 technology to determine if the *yellow-y* gene plays a crucial role in the process of cuticular melanin synthesis in *A. mellifera*. They targeted this gene due to its great potential for mutants screening, being a selectable marker. By disrupting it, the phenotype of worker cuticle has changed, mainly due to the black pigment decreasing, thus confirming the *yellow-y* gene critical role in melanin pigmentation. However, as future prospects, this could be a great genetic marker for upcoming genomic research [72].

Referring to *A. mellifera* sex determination, it is controlled by the heterozygosity at a particular locus that harbors the key *complementary sex determiner (csd)* gene. The bees that are heterozygous at this specific locus are females, while the males are homozygous or hemizygous [73]. In a recent study, Wang et al. (2021) [74] used the CRISPR-Cas9 tool in order to knock out the *csd* gene and, thus, eliminated the genetic difference between females and males. Subsequently, they aimed to observe the transcriptome difference between the two sexes in this particular genetic background. They also successfully induced target mutations in mutant haploid individuals. It was observed that the expression level of several male-biased genes was higher in the mutant males. On the other hand, the expression level of several specific female-biased genes was lower. Their data also confirmed that *csd* interacts with certain genes, such as *fruitless*, *troponin T*, and *transformer-2* just to mention a few [74].

References

1. Moon, S.B.; Kim, D.Y.; Ko, J.H.; Kim, Y.S. Recent advances in the CRISPR genome editing tool set. *Exp. Mol. Med.* 2019, 51, 1–11.
2. Guha, T.K.; Wai, A.; Hausner, G. Programmable Genome Editing Tools and their Regulation for Efficient Genome Engineering. *Comput. Struct. Biotechnol. J.* 2017, 15, 146–160.
3. Li, H.; Yang, Y.; Hong, W.; Huang, M.; Wu, M.; Zhao, X. Applications of genome editing technology in the targeted therapy of human diseases: Mechanisms, advances and prospects. *Signal Transduct. Target. Ther.* 2020, 5, 1–23.
4. Schuijff, M.; De Jong, M.D.T.; Dijkstra, A.M. AQ methodology study on divergent perspectives on CRISPR-Cas9 in the Netherlands. *BMC Med. Ethics* 2021, 22, 48.
5. Zhang, D.; Hussain, A.; Manghwar, H.; Xie, K.; Xie, S.; Zhao, S.; Larkin, R.M.; Qing, P.; Jin, S.; Ding, F. Genome editing with the CRISPR-Cas system: An art, ethics and global regulatory perspective. *Plant Biotechnol. J.* 2020, 18, 1651–1669.

6. Li, P.; Wang, L.; Yang, J.; Di, L.; Li, J. Applications of the CRISPR-Cas system for infectious disease diagnostics. *Expert Rev. Mol. Diagn.* 2021, 21, 723–732.
7. Jinek, M.; Chylinski, K.; Fonfara, I.; Hauer, M.; Doudna, J.A.; Charpentier, E. A Programmable Dual-RNA—Guided DNA endonuclease in adaptive bacterial immunity. *Science* 2012, 337, 816–822.
8. Nidhi, S.; Anand, U.; Oleksak, P.; Tripathi, P.; Lal, J.A.; Thomas, G.; Kuca, K.; Tripathi, V. Novel CRISPR—Cas Systems: An Updated Review of the Current Achievements, Applications, and Future Research Perspectives. *Int. J. Mol. Sci.* 2021, 22, 3327.
9. Hahn, F.; Loures, L.S.; Sparks, C.A.; Kanyuka, K.; Nekrasov, V. Efficient CRISPR/Cas-Mediated Targeted Mutagenesis in Spring and Winter Wheat Varieties. *Plants* 2021, 10, 1481.
10. Hesami, M.; Yoosefzadeh Najafabadi, M.; Adamek, K.; Torkamaneh, D.; Jones, A.M.P. Synergizing off-target predictions for in silico insights of CENH3 Knockout in Cannabis through CRISPR/Cas. *Molecules* 2021, 26, 2053.
11. Ishino, Y.; Shinagawa, H.; Makino, K.; Amemura, M.; Nakata, A. Nucleotide Sequence of the *iap* Gene, Responsible for Alkaline Phosphatase Isozyme Conversion in *Escherichia coli*, and Identification of the Gene Product. *J. Bacteriol.* 1987, 169, 5429–5433.
12. Gophna, U.; Brodt, A. CRISPR/Cas systems in archaea. *Mob. Genet. Elem.* 2012, 2, 63–64.
13. Horvath, P.; Barrangou, R. CRISPR/Cas, the immune system of Bacteria and Archaea. *Science* 2010, 327, 167–170.
14. Shabbir, M.A.B.; Shabbir, M.Z.; Wu, Q.; Mahmood, S.; Sajid, A.; Maan, M.K.; Ahmed, S.; Naveed, U.; Hao, H.; Yuan, Z. CRISPR-cas system: Biological function in microbes and its use to treat antimicrobial resistant pathogens. *Ann. Clin. Microbiol. Antimicrob.* 2019, 18, 21.
15. Rath, D.; Amlinger, L.; Rath, A.; Lundgren, M. The CRISPR-Cas immune system: Biology, mechanisms and applications. *Biochimie* 2015, 117, 119–128.
16. Faure, G.; Shmakov, S.A.; Yan, W.X.; Cheng, D.R.; Scott, D.A.; Peters, J.E.; Makarova, K.S.; Koonin, E.V. CRISPR—Cas in mobile genetic elements: Counter-defence and beyond. *Nat. Rev. Microbiol.* 2019, 17, 513–525.
17. McDonald, N.D.; Regmi, A.; Morreale, D.P.; Borowski, J.D.; Boyd, E.F. CRISPR-Cas systems are present predominantly on mobile genetic elements in *Vibrio* species. *BMC Genom.* 2019, 20, 105.
18. Haft, D.H.; Selengut, J.; Mongodin, E.F.; Nelson, K.E. A Guild of 45 CRISPR-Associated (Cas) Protein Families and Multiple CRISPR/Cas Subtypes Exist in Prokaryotic Genomes. *PLoS Comput. Biol.* 2005, 1, e60.
19. Makarova, K.S.; Haft, D.H.; Barrangou, R.; Brouns, S.J.J.; Charpentier, E.; Horvath, P.; Moineau, S.; Mojica, F.J.M.; Wolf, Y.I.; Yakunin, A.F.; et al. Evolution and classification of the CRISPR-Cas systems. *Nat. Rev. Microbiol.* 2011, 9, 467–477.
20. Makarova, K.S.; Koonin, E.V. Annotation and Classification of CRISPR-Cas Systems. In *CRISPR*; Springer: Berlin/Heidelberg, Germany, 2015; pp. 1–27.
21. Koonin, E.V.; Makarova, K.S. Origins and evolution of CRISPR-Cas systems. *Philos. Trans. R. Soc. B* 2019, 374, 20180087.
22. Alkhnbashi, O.S.; Shah, S.A.; Garrett, R.A.; Saunders, S.J.; Costa, F.; Backofen, R. Characterizing leader sequences of CRISPR loci. *Bioinformatics* 2016, 32, i576–i585.
23. Alkhnbashi, O.S.; Costa, F.; Shah, S.A.; Garrett, R.A.; Saunders, S.J.; Backofen, R. CRISPRstrand: Predicting repeat orientations to determine the crRNA-encoding strand at CRISPR loci. *Bioinformatics* 2014, 30, i489–i496.
24. McGinn, J.; Marraffini, L.A. Molecular mechanisms of CRISPR—Cas spacer acquisition. *Nat. Rev. Microbiol.* 2018, 17, 7–12.
25. Sorek, R.; Lawrence, C.M.; Wiedenheft, B. CRISPR-Mediated Adaptive Immune Systems in Bacteria and Archaea. *Annu. Rev. Biochem.* 2013, 82, 237–266.
26. Roberts, A.; Barrangou, R. Applications of CRISPR-Cas systems in lactic acid bacteria. *FEMS Microbiol. Rev.* 2020, 44, 523–537.
27. Hryhorowicz, M.; Lipiński, D.; Zeyland, J.; Słomski, R. CRISPR/Cas9 Immune System as a Tool for Genome Engineering. *Arch. Immunol. Ther. Exp.* 2016, 65, 233–240.
28. Terns, M.P.; Terns, R.M. CRISPR-based adaptive immune systems. *Curr. Opin. Microbiol.* 2011, 14, 321–327.
29. Newsom, S.; Parameshwaran, H.P.; Martin, L.; Rajan, R. The CRISPR-Cas Mechanism for Adaptive Immunity and Alternate Bacterial Functions Fuels Diverse Biotechnologies. *Front. Cell. Infect. Microbiol.* 2021, 10, 1–10.
30. Marraffini, L.A.; Sontheimer, E.J. CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea. *Nat. Rev. Genet.* 2010, 11, 181–190.

31. Ishino, Y.; Krupovic, M.; Forterre, P. History of CRISPR-Cas from Encounter with a Mysterious Repeated Sequence to Genome Editing Technology. *J. Bacteriol.* 2018, 200, e00580-17.
32. Sontheimer, E.J.; Barrangou, R. The Bacterial Origins of the CRISPR Genome-Editing Revolution. *Hum. Gene Ther.* 2015, 26, 413–424.
33. El-Mounadi, K.; Morales-Florian, M.L.; Garcia-Ruiz, H. Principles, Applications, and Biosafety of Plant Genome Editing Using CRISPR-Cas9. *Front. Plant Sci.* 2020, 11, 56.
34. Agustín-Pavón, C.; Isalan, M. Synthetic biology and therapeutic strategies for the degenerating brain. *Bioessays* 2014, 36, 979–990.
35. Chen, L.; Tang, L.; Xiang, H.; Jin, L.; Li, Q.; Dong, Y.; Wang, W.; Zhang, G. Advances in genome editing technology and its promising application in evolutionary and ecological studies. *Gigascience* 2014, 3, 2047-217X.
36. Tavakoli, K.; Pour-Aboughadareh, A.; Kianersi, F.; Pocza, P.; Etminan, A.; Shooshtari, L. Applications of CRISPR-Cas9 as an Advanced Genome Editing System in Life Sciences. *BioTech* 2021, 10, 14.
37. Guha, T.K.; Edgell, D.R. Applications of Alternative Nucleases in the Age of CRISPR/Cas9. *Int. J. Mol. Sci.* 2017, 18, 2565.
38. Khan, S.H. Genome-Editing Technologies: Concept, Pros, and Cons of Various Genome-Editing Techniques and Bioethical Concerns for Clinical Application. *Mol. Ther. Nucleic Acids* 2019, 16, 326–334.
39. Chira, S.; Gulei, D.; Hajitou, A.; Zimta, A.A.; Cordelier, P.; Berindan-Neagoe, I. CRISPR/Cas9: Transcending the Reality of Genome Editing. *Mol. Ther. Nucleic Acids* 2017, 7, 211–222.
40. Manghwar, H.; Lindsey, K.; Zhang, X.; Jin, S. CRISPR/Cas System: Recent Advances and Future Prospects for Genome Editing. *Trends Plant Sci.* 2019, 24, 1102–1125.
41. Li, J.; Shi, Y.; Wu, J.; Li, H.; Smagghe, G.; Liu, T. CRISPR/Cas9 in lepidopteran insects: Progress, application and prospects. *J. Insect Physiol.* 2021, 135, 104325.
42. Tyagi, S.; Kumar, R.; Das, A.; Won, S.Y.; Shukla, P. CRISPR-Cas9 system: A genome-editing tool with endless possibilities. *J. Biotechnol.* 2020, 319, 36–53.
43. Zhang, Y.; Showalter, A.M. CRISPR/Cas9 Genome Editing Technology: A Valuable Tool for Understanding Plant Cell Wall Biosynthesis and Function. *Front. Plant Sci.* 2020, 11, 589517.
44. Collias, D.; Beisel, C.L. CRISPR technologies and the search for the PAM-free nuclease. *Nat. Commun.* 2021, 12, 1–12.
45. Yang, H.; Ren, S.; Yu, S.; Pan, H.; Li, T.; Ge, S.; Zhang, J.; Xia, N. Methods Favoring Homology-Directed Repair Choice in Response to CRISPR/Cas9 Induced-Double Strand Breaks. *Int. J. Mol. Sci.* 2020, 21, 6461.
46. Bernheim, A.; Calvo-villamañán, A.; Basier, C.; Cui, L.; Rocha, E.; Touchon, M.; Bikard, D. Inhibition of NHEJ repair by type II-A CRISPR-Cas systems in bacteria. *Nat. Commun.* 2017, 8, 25–28.
47. Di Stazio, M.; Foschi, N.; Athanasakis, E.; Gasparini, P.; d'Adamo, A.P. Systematic analysis of factors that improve homologous direct repair (HDR) efficiency in CRISPR/Cas9 technique. *PLoS ONE* 2021, 16, e0247603.
48. Zhu, H.; Li, C.; Gao, C. Applications of CRISPR–Cas in agriculture and plant biotechnology. *Nat. Rev. Mol. Cell Biol.* 2020, 21, 661–677.
49. Douris, V.; Denecke, S.; Van Leeuwen, T.; Bass, C.; Nauen, R.; Vontas, J. Using CRISPR/Cas9 genome modification to understand the genetic basis of insecticide resistance: *Drosophila* and beyond. *Pestic. Biochem. Physiol.* 2020, 167, 104595.
50. Tyagi, S.; Kesiraju, K.; Saakre, M.; Rathinam, M.; Raman, V.; Pattanayak, D.; Sreevathsa, R. Genome Editing for Resistance to Insect Pests: An Emerging Tool for Crop Improvement. *ACS Omega* 2020, 5, 20674–20683.
51. Yang, Y.; Xu, J.; Ge, S.; Lai, L. CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research. *Front. Med.* 2021, 8, 649896.
52. Yang, Y.; Liu, X.; Li, S.; Chen, Y.; Zhao, Y.; Wei, Y.; Qiu, Y.; Liu, Y.; Zhou, Z.; Han, J.; et al. Genome-scale CRISPR screening for potential targets of ginsenoside compound K. *Cell Death Dis.* 2020, 11, 39.
53. Xu, Y.; Li, Z. CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy. *Comput. Struct. Biotechnol. J.* 2020, 18, 2401–2415.
54. Ma, X.; He, K.; Shi, Z.; Li, M.; Li, F.; Chen, X.-X. Large-Scale Annotation and Evolution Analysis of MiRNA in Insects. *Genome Biol. Evol.* 2021, 13, evab083.
55. Brady, D.; Grapputo, A.; Romoli, O.; Sandrelli, F. Insect Cecropins, Antimicrobial Peptides with Potential Therapeutic Applications. *Int. J. Mol. Sci.* 2019, 20, 5862.

56. Romoli, O.; Mukherjee, S.; Mohid, S.A.; Dutta, A.; Montali, A.; Franzolin, E.; Brady, D.; Zito, F.; Bergantino, E.; Rampazzo, C.; et al. Enhanced Silkworm Cecropin B Antimicrobial Activity against *Pseudomonas aeruginosa* from Single Amino Acid Variation. *ACS Infect. Dis.* 2019, 5, 1200–1213.
57. Cui, Y.; Sun, J.; Yu, L. Application of the CRISPR gene-editing technique in insect functional genome studies—A review. *Entomol. Exp. Appl.* 2017, 162, 124–132.
58. De Lazzari, F.; Sandrelli, F.; Whitworth, A.J.; Bisaglia, M. Antioxidant Therapy in Parkinson's Disease: Insights from *Drosophila melanogaster*. *Antioxidants* 2020, 9, 52.
59. Taning, C.N.T.; Van Eynde, B.; Yu, N.; Ma, S.; Smagghe, G. CRISPR/Cas9 in insects: Applications, best practices and biosafety concerns. *J. Insect Physiol.* 2017, 98, 245–257.
60. Hu, X.F.; Zhang, B.; Liao, C.H.; Zeng, Z.J. High-Efficiency CRISPR/Cas9-Mediated Gene Editing in Honeybee (*Apis mellifera*) Embryos. *G3 Genes Genomes Genet.* 2019, 9, 1759–1766.
61. Gratz, S.J.; Cummings, A.M.; Nguyen, J.N.; Hamm, D.C.; Donohue, L.K.; Harrison, M.M.; Wildonger, J.; O'Connor-giles, K.M. Genome Engineering of *Drosophila* with the CRISPR RNA-guided Cas9 nuclease. *Genetics* 2013, 194, 1029–1035.
62. Yu, Z.; Ren, M.; Wang, Z.; Zhang, B.; Rong, Y.S.; Jiao, R.; Gao, G. Highly Efficient Genome Modifications Mediated by CRISPR/Cas9 in *Drosophila*. *Genetics* 2013, 195, 289–291.
63. Perry, T.; Batterham, P. Harnessing model organisms to study insecticide resistance. *Curr. Opin. Insect Sci.* 2018, 27, 61–67.
64. Homem, R.A.; Davies, T.G.E. An overview of functional genomic tools in deciphering insecticide resistance. *Curr. Opin. Insect Sci.* 2018, 27, 103–110.
65. Scott, J.G.; Buchon, N. *Drosophila melanogaster* as a powerful tool for studying insect toxicology. *Pestic. Biochem. Physiol.* 2019, 161, 95–103.
66. Matsuoka, Y.; Nakamura, T.; Watanabe, T.; Barnett, A.A.; Noji, S.; Mito, T.; Extavour, C.G. Establishment of CRISPR/Cas9-based knock-in in a hemimetabolous insect: Targeted gene tagging in the cricket *Gryllus bimaculatus*. *bioRxiv* 2021.
67. Donoughe, S.; Extavour, C.G. Embryonic development of the cricket *Gryllus bimaculatus*. *Dev. Biol.* 2016, 411, 140–156.
68. Evans, J.D.; Aronstein, K.; Chen, Y.P.; Hetru, C.; Imler, J.; Jiang, H.; Kanost, M.; Thompson, G.J.; Zou, Z.; Hultmark, D. Immune pathways and defence mechanisms in honey bees *Apis mellifera*. *Insect Mol. Biol.* 2006, 15, 645–656.
69. Cucu, A.A.; Baci, G.M.; Moise, A.R.; Dezs, S.; Marc, B.D.; Stângaciu, S.; Dezmiream, D.S. Towards a Better Understanding of Nutritional and Therapeutic Effects of Honey and Their Applications in Apitherapy. *Appl. Sci.* 2021, 11, 4190.
70. Baci, G.; Cucu, A.; Moise, A.R.; Dezmiream, D.S. Applicability of Honey on Silkworms (*Bombyx mori*) and Quality Improvement of Its Biomaterials. *Appl. Sci.* 2021, 11, 4613.
71. Kohno, H.; Suenami, S.; Takeuchi, H.; Sasaki, T.; Kubo, T. Production of Knockout Mutants by CRISPR/Cas9 in the European Honeybee, *Apis mellifera* L. *Zool. Sci.* 2016, 33, 505–512.
72. Nie, H.; Liang, L.; Li, Q.; Li, Z.; Zhu, Y.; Guo, Y.; Zheng, Q.; Lin, Y.; Yang, D.; Li, Z.; et al. CRISPR/Cas9 mediated knockout of Amyellow-y gene results in melanization defect of the cuticle in adult *Apis mellifera*. *J. Insect Physiol.* 2021, 132, 104264.
73. Gempe, T.; Hasselmann, M.; Schiøtt, M.; Hause, G.; Otte, M.; Beye, M. Sex Determination in Honeybees: Two Separate Mechanisms Induce and Maintain the Female Pathway. *PLoS Biol.* 2009, 7, e1000222.
74. Wang, X.; Lin, Y.; Liang, L.; Geng, H.; Zhang, M.; Nie, H.; Su, S. Transcriptional Profiles of Diploid Mutant *Apis mellifera* Embryos after Knockout of *csd* by CRISPR/Cas9. *Insects* 2021, 12, 704.